These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32189935)

  • 1. Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab.
    Amjad W; Kotiah S; Gupta A; Morris M; Liu L; Thuluvath PJ
    J Clin Exp Hepatol; 2020; 10(2):185-187. PubMed ID: 32189935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research.
    Gassmann D; Weiler S; Mertens JC; Reiner CS; Vrugt B; Nägeli M; Mangana J; Müllhaupt B; Jenni F; Misselwitz B
    Transplant Direct; 2018 Aug; 4(8):e376. PubMed ID: 30255136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
    Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases.
    Al Jarroudi O; Ulusakarya A; Almohamad W; Afqir S; Morere JF
    Cureus; 2020 Oct; 12(10):e11150. PubMed ID: 33133796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of checkpoint inhibitors in liver transplant recipients.
    Munker S; De Toni EN
    United European Gastroenterol J; 2018 Aug; 6(7):970-973. PubMed ID: 30228883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.
    Ho CM; Chen HL; Hu RH; Lee PH
    Ther Adv Med Oncol; 2019; 11():1758835919843463. PubMed ID: 31065295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
    Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
    APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B; McBride A; Scott AJ
    Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.
    Aguirre LE; Guzman ME; Lopes G; Hurley J
    Oncologist; 2019 Mar; 24(3):394-401. PubMed ID: 30413665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma.
    Sheng QJ; Tian WY; Dou XG; Zhang C; Li YW; Han C; Fan YX; Lai PP; Ding Y
    World J Gastrointest Oncol; 2020 Nov; 12(11):1255-1271. PubMed ID: 33250959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report.
    Nishikawa K; Okuma Y; Hashimoto K; Kashima J
    Tohoku J Exp Med; 2019 Apr; 247(4):247-250. PubMed ID: 30996212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma.
    Friend BD; Venick RS; McDiarmid SV; Zhou X; Naini B; Wang H; Farmer DG; Busuttil RW; Federman N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
    Wehrenberg-Klee E; Goyal L; Dugan M; Zhu AX; Ganguli S
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1799-1802. PubMed ID: 29845347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
    Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
    Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
    Roth GS; Decaens T
    Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.